OverviewSuggest Edit

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.

TypePublic
Founded1988
HQTarrytown, NY, US
Websiteregeneron.com
Employee Ratings4
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)8,100(+10%)
Revenue (FY, 2020)$8.5 B(+9%)
Share Price (Feb 2021)$494.9
Cybersecurity ratingCMore

Key People/Management at Regeneron Pharmaceuticals

Leonard S. Schleifer

Leonard S. Schleifer

Co-Founder, President and Chief Executive Officer
George D. Yancopoulos

George D. Yancopoulos

Co-Founder, President and Chief Scientific Officer
Nouhad Husseini

Nouhad Husseini

Senior Vice President, Business Development
Robert E. Landry

Robert E. Landry

Executive Vice President, Finance and Chief Financial Officer
Joseph J. LaRosa

Joseph J. LaRosa

Executive Vice President, General Counsel and Secretary
Marion McCourt

Marion McCourt

Senior Vice President, Commercial
Show more

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations
Tarrytown, NY, US (HQ)
777 Old Saw Mill River Rd
Bernards, NJ, US
110 Allen Rd, Basking Ridge
Rensselaer, NY, US
81 Columbia Turnpike
Sleepy Hollow, NY, US
1 Rockwood Rd
Washington, DC, US
1399 New York Ave NW
Dublin, IE
Harcourt St
Show all (8)

Regeneron Pharmaceuticals Financials and Metrics

Regeneron Pharmaceuticals Revenue

Regeneron Pharmaceuticals's revenue was reported to be $8.50 b in FY, 2020
USD

Revenue (FY, 2020)

8.5b

Net income (FY, 2020)

3.5b

EBIT (FY, 2020)

3.6b

Market capitalization (8-Feb-2021)

52.8b

Closing stock price (8-Feb-2021)

494.9

Cash (31-Dec-2020)

2.2b

EV

53.3b
Regeneron Pharmaceuticals's current market capitalization is $52.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.9b5.9b6.7b7.9b8.5b

Revenue growth, %

18%21%14%17%

Cost of goods sold

299.7m397.1m434.1m782.2m

Gross profit

4.6b5.5b6.3b7.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.3b1.5b1.5b1.5b1.6b1.7b1.7b1.9b2.0b1.8b1.2b1.5b

Cost of goods sold

84.2m102.9m104.2m114.9m91.7m110.4m179.2m152.5m226.6m102.5m

Gross profit

1.2b1.4b1.4b1.4b1.5b1.6b1.5b1.8b1.8b1.1b

Gross profit Margin, %

94%93%93%92%94%93%90%92%89%92%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

535.2m812.7m1.5b1.6b2.2b

Accounts Receivable

1.6b2.0b2.2b2.7b3.1b

Prepaid Expenses

130.5m225.0m243.3m387.1m160.8m

Inventories

399.4m726.1m1.2b1.4b1.9b
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

895.5m1.2b2.4b2.1b3.5b

Depreciation and Amortization

104.7m145.5m148.2m210.3m235.9m

Inventories

(149.8m)(314.2m)(387.9m)(335.5m)(529.4m)

Accounts Payable

254.0m(23.2m)210.0m444.5m118.9m
USDFY, 2016

Revenue/Employee

900.1k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.6 x
Show all financial metrics

Regeneron Pharmaceuticals Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patents (US)

6 17 18 21

Product Candidates

16 15 21 22

Products

5 6 7 7

Trademarks

8 9 12 13
Show all operating metrics

Regeneron Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Loop Road Holdings LLC
Old Saw Mill Holdings LLC
OSMR Holdings
OSMR International
OSMR LLC
Regeneron Assurance
Regeneron Atlantic Holdings
Regeneron Belgium BVBA
Regeneron Capital International B.V.
Regeneron Genetics Center LLC
Show more

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other

Regeneron Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Regeneron Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Regeneron Pharmaceuticals Online and Social Media Presence

Embed Graph

Regeneron Pharmaceuticals Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    C+

    72/100

  • Compensation

    B-

    74/100

Learn more on Comparably

Regeneron Pharmaceuticals News and Updates

Regeneron Pharmaceuticals Earns Top Buy Rating For November

Just because a company has a good quarter in the past doesn’t mean that their stock prices will continue to rise in the future. That’s why our AI models provide an in-depth look at a company’s financials and performance so you can make the best decisions for your portfolio.

Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders. On June 24, 2020, the U.S. Attorney's Office filed a complaint against...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc.

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). The investigation concerns whether Regeneron and certain of its officers and/or directors have breached...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc.

NEW YORK, July 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). If you are a Regeneron shareholder and wish to...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

SAN FRANCISCO, July 2, 2020 /PRNewswire/ -- Hagens Berman urges longtime shareholders in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to submit their losses now. The firm is investigating whether Regeneron's directors breached their fiduciary duties. Relevant Holding Period: At least...

Thinking about trading options or stock in Enphase Energy, Home Depot, Perrigo, Regeneron Pharmaceuticals, or Trade Desk?

NEW YORK, Feb. 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENPH, HD, PRGO, REGN, and TTD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
Show more

Regeneron Pharmaceuticals Blogs

Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial

Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial Content Import Thu, 02/25/2021 - 07:04 Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab)…

FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

TARRYTOWN, N.Y. and PARIS , Feb. 22, 2021 /PRNewswire/ --  Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials This is the third approval for Libtayo in

U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation

U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation Content Import Thu, 02/11/2021 - 17:05 U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation …

FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol

FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol Content Import Thu, 02/11/2021 - 14:01 FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol …

FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

TARRYTOWN, N.Y. and PARIS , Feb. 9, 2021 /PRNewswire/ -- Following Priority Review Libtayo receives full approval in locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCC Libtayo now approved for patients with advanced stages of the two most common skin cancers in

Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021

Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021 Content Import Thu, 01/21/2021 - 12:00 Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021 January 21, 2021 a…
Show more

Regeneron Pharmaceuticals Frequently Asked Questions

  • When was Regeneron Pharmaceuticals founded?

    Regeneron Pharmaceuticals was founded in 1988.

  • Who are Regeneron Pharmaceuticals key executives?

    Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, George D. Yancopoulos and Nouhad Husseini.

  • How many employees does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 8,100 employees.

  • What is Regeneron Pharmaceuticals revenue?

    Latest Regeneron Pharmaceuticals annual revenue is $8.5 b.

  • What is Regeneron Pharmaceuticals revenue per employee?

    Latest Regeneron Pharmaceuticals revenue per employee is $1 m.

  • Who are Regeneron Pharmaceuticals competitors?

    Competitors of Regeneron Pharmaceuticals include Catalent, Bristol-Myers Squibb and Idorsia.

  • Where is Regeneron Pharmaceuticals headquarters?

    Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.

  • Where are Regeneron Pharmaceuticals offices?

    Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations.

  • How many offices does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 8 offices.